Partners
GlaxoSmithKline
GSK and Signum have undertaken a broad R&D collaboration to develop an array of PP2A targeted drugs for the disease modifying treatment of AD. Signum's technologies bridge the link between PP2A methylation, tau hyperphosphorylation and disease providing a novel approach for AD therapeutics. Signum's partnership with GSK furthers Signum's position as an innovative biotech company, advancing pioneering drug discovery and bringing GSK's capabilities in clinical development and commercialization.
GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Rohto Pharmaceutical Co., Ltd
Rohto is a Japan-based company that manufactures and sells a wide range of products including skincare, eye care, and oral medicines. Headquartered in Osaka, Rohto has 20 subsidiaries and five associated companies, giving them broad reach in the Japanese consumer markets. We will jointly develop new applications and products and solidify the research partnership with Rohto's RVK (Research Village Kyoto) facility. Our partnership will contribute to Rohto's strategic goals, while enhancing the commercial, business development and market focus of Signum's technologies. We look forward to a productive and long-term relationship.
Research Partners
Signum has been received grant funding from federal and research foundation sources that have allowed critical advancement of our science and validate its importance.
The National Institutes of Health (NIH) is an agency of the United States Department of Health and Human Services and is the primary agency of the United States government responsible for biomedical and health-related research.
The Alzheimer's Drug Discovery Foundation was established in 2004 as a public charity to support the advancement of drugs to prevent, treat, and cure Alzheimer's disease, related dementias, and cognitive aging. Since 1998, the ADDF has granted more than $47.5 million to fund over 340 Alzheimer's drug discovery programs and clinical trials in academic centers and biotechnology companies in 19 countries. Scientists funded by the ADDF have tested over 20 new treatments in people with Alzheimer's disease.
The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today.
Research Collaborators
Signum has productive collaborations with a number of leading researchers and institutions to advance our programs and advance the scientific foundation of our platform.
Princeton University
Signum has extensive ongoing interaction with the Research laboratory of Dr. Jeffry Stock in the Dept. of Molecular Biology. Signum licensed its foundational PP2A and AFC technology from Dr. Stock's laboratory and his laboratory continues to do basic research to elucidate the underlying biochemistry of these systems. Dr. Stock's laboratory has been able to perform various sophisticated tests on some of Signum's active agents, and continues to be a source of knowledge and expertise.
New York State Institute for Basic Research in Developmental Disabilities
In collaboration with Dr. Khalid Iqbal, a pioneer in Alzheimer's neurofibrillary degeneration Professor and Chairman, Department of Neurochemistry, at the NY State Institute for Basic Research, Dr. Iqbal's lab is exploring the effects of our STMs in various rat and mouse models for Alzheimer's.
Angus C. Nairn, Yale University
Dr. Nairn is the Charles B. G. Murphy Professor of Psychiatry and Professor of Pharmacology at Yale School of Medicine. He is an expert in the structure and function of protein kinases and phosphatases. His particular interests have focused around dopaminergic signal transduction with implications for a broad range of neurological conditions including Parkinson's disease, schizophrenia and ADHD.
Donald C. Lo, Duke University
Dr. Lo is Co-Director of the Center for Drug Discovery at Duke University. His work focuses on translating basic neuroscience research into identification of novel therapeutics for neurodegenerative disorders. Application of high content screening techniques in intact neural tissues forms the cornerstone of his work in the areas of Huntington's Alzheimer's and Parkinson's diseases.
M. Maral Mouradian, UMDNJ
Dr. Mouradian is the William Dow Lovett Professor of Neurology and Director of the Center for Neurodegenerative and Neuroimmunologic Diseases at the University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School. Her work focuses on the molecular pathogenesis of Parkinson's disease and follows an extensive career that has led to the development of important therapeutics for treatment of this disease.
Rutgers University and University of Medicine and Dentistry of New Jersey
In collaboration with Dr. Ann Stock, professor at Rutgers/UMDNJ, a Howard Hughes Medical Institute investigator and an expert in structure/function analysis of signaling transduction proteins, Dr. Stock's lab is performing crystallographic studies with our PPM small molecules and PP2A.
